Subtopic Deep Dive
Dengue Vaccine Development
Research Guide
What is Dengue Vaccine Development?
Dengue vaccine development encompasses research on tetravalent vaccine candidates like Dengvaxia and TAK-003, focusing on immunogenicity, safety across DENV serotypes, and post-licensure effectiveness in endemic regions.
Key candidates include Sanofi Pasteur's Dengvaxia (Flasche et al., 2016) and Takeda's TAK-003 (Rivera et al., 2021), evaluated for long-term safety and efficacy. Studies address serotype-specific severity risks (Soo et al., 2016) and modeling of public health impact. Over 200 papers document clinical trials and meta-analyses since 2010.
Why It Matters
Dengvaxia reduces dengue burden in moderate-to-high endemicity areas but requires careful serostatus screening to avoid risks in naive individuals (Flasche et al., 2016). TAK-003 shows 80% efficacy against virologically confirmed dengue after three years across serotypes (Rivera et al., 2021). These vaccines complement vector control in hyperendemic regions like Asia and Latin America, potentially averting millions of cases annually (Wu et al., 2010).
Key Research Challenges
Antibody-Dependent Enhancement Risk
Vaccination of seronegative individuals increases severe dengue risk due to ADE, as modeled for Dengvaxia (Flasche et al., 2016). Balancing protection across serostatus remains critical. Meta-analysis confirms higher severity in secondary infections by certain serotypes (Soo et al., 2016).
Tetravalent Immunogenicity Balance
Achieving balanced immunity against all four DENV serotypes proves challenging, with TAK-003 showing variable serotype responses (Rivera et al., 2021). Long-term durability requires extended trials. Serotype-specific severity complicates endpoint selection (Soo et al., 2016).
Post-Licensure Effectiveness Monitoring
Real-world effectiveness varies by transmission intensity, necessitating ongoing surveillance post-Dengvaxia rollout (Flasche et al., 2016). Cost-effectiveness models highlight implementation hurdles in low-exposure areas. Vector dynamics influence vaccine impact (Weetman et al., 2018).
Essential Papers
Aedes Mosquitoes and Aedes-Borne Arboviruses in Africa: Current and Future Threats
David Weetman, Basile Kamgang, Athanase Badolo et al. · 2018 · International Journal of Environmental Research and Public Health · 292 citations
The Zika crisis drew attention to the long-overlooked problem of arboviruses transmitted by Aedes mosquitoes in Africa. Yellow fever, dengue, chikungunya and Zika are poorly controlled in Africa an...
Dengue Fever in Mainland China
Jin-Ya Wu, Zhao‐Rong Lun, Anthony A. James et al. · 2010 · American Journal of Tropical Medicine and Hygiene · 288 citations
Dengue is an acute emerging infectious disease transmitted by Aedes mosquitoes and has become a serious global public health problem. In mainland China, a number of large dengue outbreaks with seri...
Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections
Kuan-Meng Soo, Bahariah Khalid, Siew Mooi Ching et al. · 2016 · PLoS ONE · 269 citations
PROSPERO CRD42015026093 (http://www.crd.york.ac.uk/PROSPERO).
Integrated Aedes management for the control of Aedes-borne diseases
David Roiz, Anne L. Wilson, Thomas W. Scott et al. · 2018 · PLoS neglected tropical diseases · 261 citations
IAM supports implementation of the World Health Organisation Global Vector Control Response (WHO GVCR) and provides a comprehensive framework for health authorities to devise and deliver sustainabl...
Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomised trials
Axel Kroeger, Audrey Lenhart, Manuel Ochoa et al. · 2006 · BMJ · 250 citations
Window curtains and domestic water container covers treated with insecticide can reduce densities of dengue vectors to low levels and potentially affect dengue transmission.
The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study
Stefan Flasche, Mark Jit, Isabel Rodríguez-Barraquer et al. · 2016 · PLoS Medicine · 229 citations
Dengvaxia has the potential to reduce the burden of dengue disease in areas of moderate to high dengue endemicity. However, the potential risks of vaccination in areas with limited exposure to deng...
Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)
Luis Rivera, Shibadas Biswal, Xavier Sáez‐Llorens et al. · 2021 · Clinical Infectious Diseases · 219 citations
Abstract Background Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have ...
Reading Guide
Foundational Papers
Start with Flasche et al. (2016) for Dengvaxia modeling fundamentals and risks; Wu et al. (2010, 288 citations) for epidemiological context in endemic regions.
Recent Advances
Rivera et al. (2021) details TAK-003 long-term data; Tsheten et al. (2021) meta-analysis on severe dengue predictors informs vaccine endpoints.
Core Methods
Live-attenuated tetravalent platforms (TAK-003), dynamic transmission modeling (Flasche et al., 2016), and serotype-specific meta-regression (Soo et al., 2016).
How PapersFlow Helps You Research Dengue Vaccine Development
Discover & Search
Research Agent uses searchPapers and exaSearch to find tetravalent vaccine trials, then citationGraph on Flasche et al. (2016) reveals 229-citation impact models linking to TAK-003 studies. findSimilarPapers expands to serotype immunogenicity papers like Rivera et al. (2021).
Analyze & Verify
Analysis Agent applies readPaperContent to extract TAK-003 efficacy data from Rivera et al. (2021), then runPythonAnalysis with pandas to compute serotype-specific hazard ratios; verifyResponse via CoVe cross-checks against Soo et al. (2016) meta-analysis. GRADE grading scores evidence from RCTs as high-quality for safety endpoints.
Synthesize & Write
Synthesis Agent detects gaps in ADE risk modeling post-Flasche et al. (2016), flags contradictions between Dengvaxia and TAK-003 immunogenicity; Writing Agent uses latexEditText and latexSyncCitations to draft review sections, latexCompile for figures, exportMermaid for vaccine trial flowcharts.
Use Cases
"Run meta-analysis on TAK-003 serotype efficacy from Rivera 2021 and similar trials"
Research Agent → searchPapers('TAK-003 dengue') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas meta-regression on hazard ratios) → GRADE high evidence report with CSV export.
"Draft LaTeX review comparing Dengvaxia and TAK-003 safety profiles"
Synthesis Agent → gap detection on Flasche 2016 + Rivera 2021 → Writing Agent → latexEditText(structured sections) → latexSyncCitations → latexCompile(PDF) with efficacy comparison table.
"Find open-source code for dengue vaccine transmission models"
Research Agent → paperExtractUrls(Flasche 2016 model papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis to replicate cost-effectiveness simulations.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ dengue vaccine papers, chaining searchPapers → citationGraph → DeepScan for 7-step verification of ADE claims from Flasche et al. (2016). Theorizer generates hypotheses on TAK-003 serotype balance by synthesizing Rivera et al. (2021) with vector papers (Weetman et al., 2018). Chain-of-Verification ensures hallucination-free efficacy summaries.
Frequently Asked Questions
What is dengue vaccine development?
Dengue vaccine development creates tetravalent vaccines like Dengvaxia and TAK-003 targeting all four DENV serotypes for safety and immunogenicity (Flasche et al., 2016; Rivera et al., 2021).
What methods dominate dengue vaccine research?
Phase 3 RCTs assess efficacy (Rivera et al., 2021), transmission models evaluate public health impact (Flasche et al., 2016), and meta-analyses quantify serotype severity (Soo et al., 2016).
What are key papers in dengue vaccines?
Flasche et al. (2016, 229 citations) models Dengvaxia cost-effectiveness; Rivera et al. (2021, 219 citations) reports TAK-003 three-year efficacy.
What open problems persist?
ADE risks in seronegatives, balanced tetravalent responses, and real-world effectiveness in varied transmission settings remain unresolved (Flasche et al., 2016; Rivera et al., 2021).
Research Dengue and Mosquito Control Research with AI
PapersFlow provides specialized AI tools for Social Sciences researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Find Disagreement
Discover conflicting findings and counter-evidence
See how researchers in Social Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Dengue Vaccine Development with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Social Sciences researchers